NVS Company Profile and Key Details

Q: Who are the executives of NVS?

Paul PenepentHead of Group Financial Reporting and AccountingMs. Marie-France TschudinPres of Innovative Medicines International & Chief Commercial OfficerDr. Shreeram Aradhye M.D.Pres of Global Drug Devel. & Chief Medical OfficerMr. Aharon Gal Ph.D.Chief Strategy & Growth OfficerMr. Steffen Lang Ph.D.Pres of OperationsDr. Samir Shah M.D.Global Head of Investor RelationsMs. Karen L. HaleChief Legal OfficerDr. Robert Kowalski Pharm.D.Chief People & Organization OfficerMr. Victor BultoPres of Innovative Medicines USMr. Richard SaynorChief Executive Officer of SandozDr. Steffen Lang Ph.D.Pres of OperationsDr. Vasant NarasimhanChief Executive OfficerMr. Harry KirschChief Financial OfficerDr. Klaus Moosmayer Ph.D.Chief Ethics, Risk & Compliance Officer

NYSE : NVS

Novartis AG

$154.03

-1.05-0.68%

At Close 4:00 PM

66.82

B+ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Novartis AG (NVS) stock declined over -0.68%, trading at $154.03 on NYSE, down from the previous close of $155.08. The stock opened at $153.24, fluctuating between $153.19 and $154.81 in the recent session.

Stock Snapshot

155.08

Prev. Close

297.32B

Market Cap

153.19

Day Low

21.54

P/E Ratio

7.15

EPS (TTM)

5.62

Cash Flow per Share

153.24

Open

1.93B

Number of Shares

154.81

Day High

94.79%

Free Float in %

22.76

Book Value

2.55M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 02, 2026	153.37	154.81	153.16	154.03	2.62M
Apr 01, 2026	154.62	156.08	154.12	155.08	1.62M
Mar 31, 2026	151.58	152.86	150.51	152.75	2M
Mar 30, 2026	150.25	150.75	149.56	150.36	2.08M
Mar 27, 2026	150.01	150.58	147.85	148.18	1.96M
Mar 25, 2026	150.47	151.78	150.15	150.75	1.21M
Mar 24, 2026	146.56	148.98	146.22	148.61	1.15M
Mar 23, 2026	147.21	148.95	146.90	148.09	1.64M
Mar 20, 2026	148.77	148.90	145.29	146.03	2.02M
Mar 19, 2026	147.81	149.32	147.15	148.19	2.37M
Mar 18, 2026	152.38	152.76	149.47	149.81	1.55M
Mar 17, 2026	155.64	155.79	154.38	154.85	2.2M
Mar 16, 2026	154.54	155.38	153.85	154.87	2.48M
Mar 13, 2026	154.69	155.96	153.18	153.44	1.95M
Mar 12, 2026	154.55	155.04	153.70	154.25	1.95M
Mar 11, 2026	155.99	156.58	154.96	155.80	5.15M
Mar 10, 2026	161.35	163.07	160.43	161.59	3.69M
Mar 09, 2026	159.52	163.08	159.22	162.79	1.75M
Mar 06, 2026	156.71	160.54	156.18	160.12	3.75M
Mar 03, 2026	162.43	164.89	160.42	164.18	3.23M

Contact Details

Basel, 4056

Switzerland

https://www.novartis.com 416 132 41111

About Company

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Stock Peers

LLY

-18.9-1.98%

Eli Lilly and Company$935.62 JNJ

-1.08-0.44%

Johnson & Johnson$243.04 ABBV

-6.185-2.88%

AbbVie Inc.$208.80 AZN

2.76+1.37%

AstraZeneca PLC$203.49 MRK

0.03+0.02%

Merck & Co., Inc.$120.87 BMY

-2.13-3.45%

Bristol-Myers Squibb Company$59.60 GSK

0.7+1.25%

GSK plc$56.69 NVO

0.495+1.36%

Novo Nordisk A/S$36.98 PFE

-0.22-0.77%

Pfizer Inc.$28.33 OGN

0.22+3.58%

Organon & Co.$6.36

Company Overview

Novartis AG (NYSE:NVS) closed at $154.03 USD, losing -$1.05 (-0.68%) from the previous close of $155.08. The stock is currently mid-range between its 52-week high and low $97.72 and $170.46. With a market capitalization of about $297.32 billion, Novartis AG is classified as a mega-cap and shows lower-than-market volatility (beta ~0.52). Key stats such as the average daily volume over the past year has been around 2.36 million shares, in line with its 52-week average. Headquartered in Basel, None, Novartis AG operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Vasant Narasimhan, the company employs approximately 75,883 people and listed since November 07, 1996. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 3.97%, SMA50 11.52%, SMA200 27.9%). The stock’s 14-day RSI is 70.7 (overbought), while the ATR of 2.64 points to moderate volatility. The stock remains sitting in the mid-range of its 52-week band, trading -1.49% below its high and over 69.38% above its low. Average 10-day trading volume of 1.92 million shares is below the 3-month average of 2.34 million, indicating normal recent market interest.

Valuation Metrics

Novartis AG trades at a P/E ratio of 21.07, slightly below the S&P 500 average, with a price-to-sales ratio of 5.3 and a price-to-book ratio of 6.39 trading at moderately above to book value. The P/FCF stands at 19.04, also below market averages.

Dividend & Fair Value

Novartis AG last paid a dividend of 3.08 per share, this equals a trailing yield of roughly 3.37%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $220.92. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Novartis AG generated EPS of $7.19 over the past year. Five-year average earnings growth is 15.38%. Wall Street analysts project EPS growth of 6.19% annually over the next five years. The latest quarter delivered EPS of $2.25. The next quarter is forecast at $2.11. Next year's EPS is expected at $8.35. Analyst sentiment is bearish. Analyst rating data shows there are 1 Strong Buy ratings, 0 Buy ratings, 0 Hold ratings, 1 Sell rating and 0 Strong Sell ratings. Price targets range from $170.00 to $118.00. The high target offers 10.37% upside. The low target suggests -23.39% downside. The mean target is $144.00. This offers -6.51% upside. Novartis AG earnings surprise history is a consistent trend of beating forecasts. The quarter that ended October 28, 2025, missed forecasts by -0.44%. The prior quarter beat by 1.68%. Over the last six quarters, Apple has recorded several small beats. These include 5.35% in July 18, 2024.

Shareholding & Insider Activity

Novartis AG has 1.94 billion shares outstanding. The public float is 1.84 billion shares, elevated short interest at 0.21% of float. This equals 3.97 million shares. The short ratio is 2.01 days. Institutional investors hold 7.05% of the float. Insiders own 0.0%.

Financial & Profitability Overview

Over the trailing twelve months, Novartis AG generated $51.72B in revenue, or $25.66 per share. Gross margin was 75.20%, operating margin 28.12%, and net profit margin 23.09%. Returns are exceptional, with ROA at 11.95% and ROE at 25.59%.
On valuation metrics, Novartis AG trades at a P/E of 21.07, P/S of 5.30 and P/B of 6.39. The current ratio is 1.12 and quick ratio is 0.89. Operationally, the company’s inventory turnover is 2.17 and cash conversion cycle is 119.63 days. Debt-to-equity is 0.80, supported by a cash flow-to-debt ratio of 0.52.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2024, Novartis AG posted revenue of $51.72B, down slightly from $46.66B in the prior quarter. Gross profit was $38.90B (margin 75.20%). Operating income was $14.54B (margin 28.1%). Net income was$11.94B (EPS $5.97).
The company ended the quarter with $13.96B in cash and short-term investments, a total debt of $26.35B, and net debt of $12.96B. Total assets were $99.95B, with equity of $46.75B. Financials further reflected stability, with operating cash flow of $14.46B, free cash flow of $11.71B, and capital expenditures of - $2.75B.

Price Forecast & Outlook

Our AI price prediction model suggests that Novartis AG stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.21%, with price expected at $154.35 by April 16, 2026, within a range of $150.14 to $158.31 3-Month Outlook: Projected rise of 69.73%, reaching $261.44 by July 01, 2026, with a range of $257.10 to $267.34. 1-Year Outlook: Projected gain of 12.37%, with price at $173.09 by April 02, 2027, within a range of $170.51 to $176.35.

Key Takeaways

Novartis AG (NYSE:NVS) shares are flat 4.14% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Novartis AG trading at a premium to the broader market with a P/E of 21.07. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $121.44, suggesting -21.16% downside. Our AI forecast model points to short-term strength (0.21% over two weeks), a medium-term rise (69.73% over three months), and a longer-term gain (12.37% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Novartis AG (NVS) stock price?

Novartis AG (NYSE: NVS) stock price is $154.03 in the last trading session. During the trading session, NVS stock reached the peak price of $154.81 while $153.19 was the lowest point it dropped to. The percentage change in NVS stock occurred in the recent session was -0.68% while the dollar amount for the price change in NVS stock was - $1.05.

NVS's industry and sector of operation?

The NYSE listed NVS is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector. Novartis AG designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of NVS?

Paul Penepent
Head of Group Financial Reporting and Accounting
Ms. Marie-France Tschudin
Pres of Innovative Medicines International & Chief Commercial Officer
Dr. Shreeram Aradhye M.D.
Pres of Global Drug Devel. & Chief Medical Officer
Mr. Aharon Gal Ph.D.
Chief Strategy & Growth Officer
Mr. Steffen Lang Ph.D.
Pres of Operations
Dr. Samir Shah M.D.
Global Head of Investor Relations
Ms. Karen L. Hale
Chief Legal Officer
Dr. Robert Kowalski Pharm.D.
Chief People & Organization Officer
Mr. Victor Bulto
Pres of Innovative Medicines US
Mr. Richard Saynor
Chief Executive Officer of Sandoz
Dr. Steffen Lang Ph.D.
Pres of Operations
Dr. Vasant Narasimhan
Chief Executive Officer
Mr. Harry Kirsch
Chief Financial Officer
Dr. Klaus Moosmayer Ph.D.
Chief Ethics, Risk & Compliance Officer

How NVS did perform over past 52-week?

NVS's closing price is 57.62% higher than its 52-week low of $97.72 where as its distance from 52-week high of $170.46 is -9.64%.

How many employees does NVS have?

Number of NVS employees currently stands at 75,883.

Link for NVS official website?

Official Website of NVS is: https://www.novartis.com

How do I contact NVS?

NVS could be contacted at phone 416 132 41111 and can also be accessed through its website. NVS operates from Lichtstrasse 35, Basel, 4056, Switzerland.

How many shares of NVS are traded daily?

NVS stock volume for the day was 2.55M shares. The average number of NVS shares traded daily for last 3 months was 2.36M.

What is the market cap of NVS currently?

The market value of NVS currently stands at $297.32B with its latest stock price at $154.03 and 1.93B of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	75883
Beta	0.5
Sales or Revenue	$51.72B
5Y Sales Change%	-0.026%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - General

NVS Company Profile and Key Details

Novartis AG

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Earnings & Analyst Outlook

Company Overview

Valuation Metrics

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways